The SABER® and Cloud™ Injectable Depot Systems
  ORADUR® Oral Delivery System
  TRANSDUR® Transdermal Technology System
  DURIN® System
  Localized Drug Delivery
  Patents
  Publications

A. Equivalents to 100 µ/hr Duragesic®, but lasts for 7 days vs. 2-3 days for Duragesic® ; B. Equivalents to 25 µ/hr Duragesic®, but lasts for 7 days vs. 2-3 days for Duragesic®
A. Equivalents to 100 µ/hr Duragesic®, but lasts for 7 days vs. 2-3 days for Duragesic® ; B. Equivalents to 25 µ/hr Duragesic®, but lasts for 7 days vs. 2-3 days for Duragesic®




By avoiding the effects on the gastrointestinal tract and first-pass metabolism seen with some oral products, transdermal drug therapies can enhance therapeutic efficacy while decreasing side effects. Over the last few decades, numerous companies have introduced to the marketplace novel therapeutic products that utilize transdermal drug delivery technology. That tradition of innovation continues to be alive and well at DURECT as we continue refining and improving various attributes of transdermal products with the development of our TRANSDUR® transdermal dosage form technologies. Developing small, non-irritating and user-friendly products with excellent skin-adhesion are the main objectives for the TRANSDUR technology, which are major differentiating factors among patients and physicians. First generation transdermal products fall short of these objectives, in part, because of their use of a liquid drug-reservoir and skin-irritating additives such as alcohols.

Depending on the drug and its physicochemical properties, the TRANSDUR® technology provides compatible and functional transdermal formulations, resulting in thin solid state transdermal products that can deliver drugs, through intact skin, at a controlled rate up to one week. TRANSDUR technology encompasses proprietary product components such as pressure sensitive adhesive formulations, skin permeation enhancers and carrier films depending on the application, which enable DURECT’s scientists to expand the range of drugs that can be delivered transdermally. Transdermal products based on TRANSDUR® technology have the potential to improve convenience and compliance as well as cost-effectiveness, and provide highly reliable therapy to patients and health care providers.

Our TRANSDUR technology is a proprietary transdermal delivery system that enables delivery of drugs continuously for up to 7 days. The TRANSDUR technology is the basis for TRANSDUR®-Sufentanil which is currently in Phase II and for which we hold worlwide rights. The TRANSDUR technology is also the basis for ELADUR, which is currently in Phase II. Phase II results are not necessarily predictive of the results of Phase III trials. There have been numerous drug candidates that have succeeded in Phase II clinical trials that have later failed in Phase III clinical trials.

Download the TRANSDUR® Fact Sheet (.PDF).

Back to top



 
 © 2000-2014 DURECT Corporation
Last updated: June 27, 2014
Search     Contact     Site Index     Legal Notice     Privacy Policy